Table 2. Meta-regression and subgroup analysis of LMR and OS of various cancers.

Subgroup	HR (95% CI)	P value	Meta-regression P value	Heterogeneity
				I2 (%)	P value
Non-hematological
Year of publication			0.276
2012–2013	0.40 (0.17–0.93)	0.034		68.7	0.074
2014	0.59 (0.52–0.67)	< 0.001		17.3	0.279
2015	0.61 (0.52–0.72)	< 0.001		65.2	< 0.001
Type of publication			0.250
Full paper	0.60 (0.54–0.67)	< 0.001		53.3	0.001
Abstract	0.39 (0.16–0.92)	0.031		61	0.109
Study design			0.782
Prospective	0.56 (0.37–0.83)	0.005		37.6	0.206
Retrospective	0.59 (0.53–0.66)	< 0.001		55.7	< 0.001
Cancer site			0.545
Cancer stage			0.004
Mixed	0.73 (0.66–0.81)	< 0.001		45.4	0.043
Non-metastatic	0.61 (0.55–0.68)	< 0.001		3.5	0.405
Metastatic	0.50 (0.45–0.57)	< 0.001		26.7	0.235
Cutoff for LMR			0.015
2.0 to < 3.0	0.51 (0.45–0.58)	< 0.001		0	0.459
3.0 to < 4.0	0.62 (0.55–0.71)	< 0.001		0	0.497
≥ 4.0	0.67 (0.56–0.80)	< 0.001		69	0.001
ROC curve			0.646
Considered	0.59 (0.53–0.66)	< 0.001		41.5	0.025
Not considered	0.58 (0.44–0.78)	< 0.001		69.2	0.006
Analysis of hazard ratio			0.950
Multivariable	0.59 (0.53–0.66)	< 0.001		58.2	< 0.001
Univariate	0.60 (0.48–0.75)	0.001		0	0.644
Hematological
Year of publication			0.181
2011–2012	0.32 (0.19–0.55)	< 0.001		63.8	0.026
2013	0.54 (0.42–0.69)	< 0.001		0	0.647
2014–2015	0.48 (0.34–0.69)	< 0.001		78.8	< 0.001
Type of publication			0.207
Full paper	0.47 (0.36–0.62)	< 0.001		78.9	< 0.001
Abstract	0.34 (0.24–0.50)	< 0.001		0	0.419
Cancer site			0.596
Cutoff for LMR			0.343
1.0 to < 2.0	0.27 (0.19–0.40)	< 0.001		19.1	0.293
2.0 to < 3.0	0.56 (0.47–0.65)	< 0.001		0	0.662
≥ 3.0	0.34 (0.23–0.49)	< 0.001		0	0.452
ROC curve			0.203
Considered	0.43 (0.35–0.54)	< 0.001		48.9	0.017
Not considered	0.57 (0.32–1.01)	0.053		62.4	0.047
Analysis of hazard ratio			0.203
Multivariable	0.43 (0.35–0.54)	< 0.001		48.9	0.017
Univariate	0.57 (0.32–1.01)	0.053		62.4	0.047

LMR, lymphocyte to monocyte ratio; OS, overall survival; HR, hazard ratio; CI, confidence interval.